Hormone Related Cancers Program

激素相关癌症计划

• 批准号: 10267042
• 负责人: STUART S MARTIN
• 金额: $ 3.96万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-08 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10267042
• 关键词: Address; Advanced Malignant Neoplasm; Affect; African American; Aromatase Inhibitors; Baltimore; Basic Science; Biology; Biometry; Breast cancer metastasis; Catchment Area; Cigarette; Clinical Research; Clinical Trials; Collaborations; Community Outreach; Comprehensive Cancer Center; County; Development; Diagnosis; Doctor of Medicine; Doctor of Philosophy; Enrollment; Flow Cytometry; Funding; Funding Agency; Genomics; Goals; Grant; Hormones; Human; Image; Institutes; Interdisciplinary Study; Intervention Trial; Investigational Therapies; Laboratories; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Maryland; Mediating; Medical; Medical center; Mission; Molecular Biology; Morbidity - disease rate; NCI Center for Cancer Research; Neoplasm Metastasis; Pathology; Patients; Peer Review; Pharmaceutical Preparations; Pharmacy Schools; Phase III Clinical Trials; Physiology; Population; Population Sciences; Public Health Schools; Publications; Recommendation; Recurrence; Research; Research Personnel; Research Priority; Resistance; Resistance development; Resources; School Dentistry; Services; Source; System; Therapeutic Intervention; Tissues; Translational Research; Underrepresented Minority; Universities; Work; acronyms; anticancer research; biobank; cancer health disparity; cancer imaging; cancer recurrence; cancer stem cell; cancer therapy; college; community engagement; demographics; disparity reduction; hormone related cancer; hormone therapy; improved; malignant breast neoplasm; medical schools; member; mortality; neoplasm immunotherapy; new technology; precision medicine; professor; programs; recruit; response; structural biology; targeted treatment; therapeutic target; treatment response; tumor; tumor immunology; virology

11.0 Abstract: Hormone Related Cancers (HRC) Program The overarching goal of the HRC Program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is to reduce the morbidity and mortality of cancers that arise from hormone-related tissues. To achieve this mission, the program focuses on three specific aims: Aim 1: Identify targets in hormone-related cancers that mediate innate and acquired resistance improves the understanding of how cancers resist hormonal therapies or develop resistance during recurrence; Aim 2: Target mechanisms that regulate cancer stem cells and promote metastasis, with a focus on defining and therapeutically targeting mechanisms of cancer recurrence; and Aim 3: Develop strategies to improve diagnosis, inform treatment, and evaluate treatment response to apply new technologies that advance cancer imaging and accelerate analysis of tumor drug response for precision medicine. To achieve these three aims, HRC members are supported by collaborators and resources throughout other UMGCCC programs as well as exceptional shared services. The HRC Program has 46 members, including 30 full members and 16 associate members, who conduct basic, translational, and clinical research chiefly in breast, prostate, and ovarian cancer with $8.7 million direct annual funding ($11.0 million total), including $3.4 million (39%) from NCI and $2.6 million from other peer-reviewed sources. HRC Program members receive $2.7 million annually from non–peer-reviewed funding sources. During this funding period, HRC members authored 506 cancer-related publications, of which 17% resulted from intraprogrammatic, 28% from interprogrammatic, 6% from intra and interprogrammatic collaborations; and 60% of publications include collaborations with external investigators, reflecting the high national impact of the HRC Program. HRC Program members manage numerous clinical trials. During this grant period, the HRC Program enrolled 1,412 patients on clinical trials, including 213 on interventional trials (200 therapeutic interventional), and 1,199 patients on non-interventional trials. 41.5% of patients were underrepresented minorities, reflecting the demographics of the catchment area. The research programs of HRC members utilize all of the UMGCCC shared services. The HRC Program collaborates with the other four UMGCCC Research Programs and engages community outreach and engagement to identify and address the cancer research priorities of the catchment area.

11.0 摘要：激素相关癌症 (HRC) 计划 马里兰大学 HRC 项目的总体目标 Marlene 和 Stewart Greenebaum 综合癌症中心 (UMGCCC) 旨在降低癌症的发病率和死亡率 为了实现这一使命，该计划重点关注三个具体目标： 目标 1：识别 介导先天性和获得性耐药性的激素相关癌症的靶点可改善 了解癌症如何抵抗激素疗法或在复发过程中产生耐药性；目标 2：目标 调节癌症干细胞和促进转移的机制，重点是定义和 目标 3：制定改善策略 诊断、告知治疗并评估治疗反应，以应用推进新技术 癌症成像和加速分析肿瘤药物反应以实现精准医疗。 目标，HRC 成员得到其他 UMGCCC 项目的合作者和资源的支持，例如 HRC 计划拥有 46 名会员，其中包括 30 名正式会员和 16 名会员。 准会员，主要从事乳腺、前列腺和前列腺方面的基础、转化和临床研究 卵巢癌每年直接资助 870 万美元（总计 1100 万美元），其中来自 NCI 的 340 万美元（39%） 来自其他同行评审来源的 260 万美元 HRC 计划成员每年从其获得 270 万美元。 在此资助期间，HRC 成员撰写了 506 篇与癌症相关的文章。 出版物，其中 17% 来自计划内，28% 来自计划间，6% 来自内部和外部 项目间合作；60% 的出版物包括与外部研究人员的合作， 反映了 HRC 计划在全国范围内的高度影响，HRC 计划成员管理着众多临床项目。 在此资助期间，HRC 计划招募了 1,412 名患者参加临床试验，其中 213 名患者参加了临床试验。 介入试验（200 名治疗性介入试验）和 1,199 名患者进行非介入试验（占 41.5%）。 患者属于少数族裔，反映了该地区的人口统计数据。 HRC 成员的计划利用 UMGCCC 的所有共享服务 HRC 计划与 其他四个 UMGCCC 研究计划，并进行社区外展和参与，以确定和 解决该流域的癌症研究重点。